{
    "clinical_study": {
        "@rank": "77152", 
        "arm_group": [
            {
                "arm_group_label": "Pitolisant", 
                "arm_group_type": "Experimental", 
                "description": "Pitolisant at 5, 10, 20 or 40mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Capsules of placebo containing lactose"
            }
        ], 
        "brief_summary": {
            "textblock": "Double blind, randomized, parallel groups study of Pitolisant versus placebo, in narcoleptic\n      patients experiencing EDS, and cataplexy (minimum of 3 complete or partial cataplexy attacks\n      per week).\n\n      The patients will be treated during 7 weeks with Pitolisant or placebo."
        }, 
        "brief_title": "Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Narcolepsy With Cataplexy", 
            "Excessive Daytime Sleepiness"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cataplexy", 
                "Narcolepsy"
            ]
        }, 
        "detailed_description": {
            "textblock": "The treatment period (7 weeks double blind) will aim at demonstrating the efficacy of\n      Pitolisant on the number of cataplexy attacks and the Excessive Daytime Sleepiness by\n      verifying whether the results of Pitolisant are superior to those of placebo.\n\n      The safety will also be assessed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n          -  Narcoleptic with cataplexy : at least 3 weekly cataplexy attacks\n\n          -  ESS > or = 12\n\n          -  ICF signed and dated\n\n        Main Exclusion Criteria:\n\n          -  Other conditions that could generate EDS\n\n          -  Psychological and neurological disorders\n\n          -  Acute or chronic severe disease\n\n          -  Treatment by prohibited medication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01800045", 
            "org_study_id": "P11-05 / Pitolisant", 
            "secondary_id": "2012-003076-39"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pitolisant", 
                "description": "1 capsule in the morning before breakfast", 
                "intervention_name": "Pitolisant", 
                "intervention_type": "Drug", 
                "other_name": "BF2.649"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "1 capsule in the morning before breakfast", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Capsules of placebo containing lactose"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Narcolepsy", 
            "Cataplexy", 
            "Sleep disorder", 
            "Excessive daytime sleepiness"
        ], 
        "lastchanged_date": "May 15, 2013", 
        "location": {
            "contact": {
                "email": "szakacs001@t-online.hu", 
                "last_name": "Zoltan SZAKACS, Pr", 
                "phone": "+36209364140"
            }, 
            "facility": {
                "address": {
                    "city": "Budapest", 
                    "country": "Hungary", 
                    "zip": "1134"
                }, 
                "name": "State Health Center"
            }, 
            "investigator": {
                "last_name": "Zoltan SZAKACS, Pr", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Hungary"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy.", 
        "overall_contact": {
            "email": "e.depaillette@bioprojet.com", 
            "last_name": "Evelyne De Paillette, Dr", 
            "phone": "0033 (0)1 47 03 66 33"
        }, 
        "overall_official": {
            "affiliation": "Bioprojet", 
            "last_name": "Evelyne De Paillette, Dr", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Bulgaria: Bulgarian Drug Agency", 
                "Czech Republic: State Institute for Drug Control", 
                "Hungary: National Institute of Pharmacy", 
                "Macedonia: Ministry of Health", 
                "Ukraine: Ministry of Health", 
                "Serbia and Montenegro: Agency for Drugs and Medicinal Devices", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Turkey: Ministry of Health", 
                "Poland: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measure of anticataplectic efficacy assessed by the change in the average number of cataplexy attacks per week.", 
            "measure": "Measure of anticataplectic efficacy", 
            "safety_issue": "No", 
            "time_frame": "At week 49"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01800045"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Excessive Daytime Sleepiness assessment by evaluation of ESS score, and other questionnaires.", 
                "measure": "Excessive Daytime Sleepiness assessment", 
                "safety_issue": "No", 
                "time_frame": "At week 7"
            }, 
            {
                "description": "Safety assessment thanks to AE recording, vitals signs assessment, ECG...", 
                "measure": "Safety assessment", 
                "safety_issue": "Yes", 
                "time_frame": "11 weeks"
            }
        ], 
        "source": "Bioprojet", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bioprojet", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}